Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026)
Erasca (ERAS) posted Total Non-Current Liabilities of $67.4 million for Q1 2026, down 4.56% on a QoQ basis from $70.6 million in Q4 2025, and down 5.77% year-over-year from $71.5 million in Q1 2025.
Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Erasca's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $67.4 million for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 5.77% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.4 million (down 5.77% YoY) and the FY2025 annual result came in at $70.6 million, down 10.27% from the prior year.
- Total Non-Current Liabilities was $67.4 million for Q1 2026 at Erasca, down from $70.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $102.5 million in Q4 2022 and bottomed at $67.4 million in Q1 2026.
- A 5-year average of $77.5 million and a median of $77.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 129.12% — and 2023, when it declined 23.85%.
- Erasca's Total Non-Current Liabilities stood at $102.5 million in 2022, then decreased by 23.85% to $78.0 million in 2023, then gained by 0.79% to $78.7 million in 2024, then fell by 10.27% to $70.6 million in 2025, then slipped by 4.56% to $67.4 million in 2026.
- Business Quant data shows ERAS's Total Non-Current Liabilities at $67.4 million in Q1 2026, $70.6 million in Q4 2025, and $72.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 67.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.37 Mn |
| Dec 31, 2025 | 70.58 Mn |
| Sep 30, 2025 | 72.12 Mn |
| Jun 30, 2025 | 72.87 Mn |
| Mar 31, 2025 | 71.49 Mn |
| Dec 31, 2024 | 78.67 Mn |
| Sep 30, 2024 | 78.51 Mn |
| Jun 30, 2024 | 74.58 Mn |
| Mar 31, 2024 | 81.05 Mn |
| Dec 31, 2023 | 78.05 Mn |
| Sep 30, 2023 | 79.67 Mn |
| Jun 30, 2023 | 77.26 Mn |
| Mar 31, 2023 | 80.46 Mn |
| Dec 31, 2022 | 102.48 Mn |
| Dec 31, 2021 | 44.73 Mn |
| Sep 30, 2021 | 38.96 Mn |
| Jun 30, 2021 | 19.58 Mn |
| Dec 31, 2020 | 15.79 Mn |